$BPTH
Bio-Path Holdings Inc
PRICE
$3.92 ▼-0.508%
Last Close
VOLUME
10,956
DAY RANGE
3.91 - 4.0936
52 WEEK
2.68 - 8.62
Join Discuss about BPTH with like-minded investors
@maletone #StockTraders.NET
decent move on $BPTH maybe it gives us a trade tomorrow
113 Replies 13 👍 12 🔥
@maletone #StockTraders.NET
but was to busy watching $BPTH and being reactive today
123 Replies 7 👍 10 🔥
@marketjay #Market Assassin Corp
honorable mention today for intraday set up BPTH
46 Replies 10 👍 8 🔥
@TraderXx #StockTraders.NET
I see $BPTH was nutty yday also, did you guys bank on it?
149 Replies 15 👍 7 🔥
Key Metrics
Market Cap
29.36 M
Beta
1.02
Avg. Volume
29.83 K
Shares Outstanding
7.16 M
Yield
0%
Public Float
0
Next Earnings Date
2022-11-14
Next Dividend Date
Company Information
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path's lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it is being evaluated in lymphoma clinical studies.
Website: www.biopathholdings.com
HQ: ,
Related News